⚠️ No article content returned.
Astrazeneca PLC (AZN)
- Written by: Madison Wilson
Latest Company News
Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer.
Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio.
The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...
Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer.
Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer.
AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.
